



BioMed Research International

Special Issue on  
***Helicobacter pylori* Infection**

# CALL FOR PAPERS

*Helicobacter pylori* (*H. pylori*) colonizes the gastric mucosa of more than 50% of the human population. It is the major etiological agent of chronic gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma. The concomitance of particular genotypes of both pathogen and host may lead to the development of serious gastroduodenal diseases.

With the rising prevalence of antimicrobial resistance, the treatment success of standard triple therapy has recently declined to unacceptable levels in most countries. Several strategies including sequential, concomitant, and hybrid therapies are therefore proposed to increase the eradication rate of first-line treatment for *H. pylori* infection. Since the best first-line eradication regimen with highest eradication rate and low adverse effects remains unclear and the exact route of transmission is still not exactly known, *H. pylori* infection continues to be a big challenge to all gastroenterologists 30 years after its discovery.

We invite investigators to contribute original research articles as well as review articles focusing on recent advances in the virulence factors of *H. pylori*, mechanism of *H. pylori*-induced gastric inflammation and carcinogenesis, promising first-line and rescue therapies, and vaccinating against *H. pylori* infection.

Potential topics include, but are not limited to:

- ▶ Epidemiology of *H. pylori* infection and public health implications
- ▶ Molecular cross-talk between *H. pylori* and human gastric mucosa
- ▶ Pathogenesis of *H. pylori* infection
- ▶ Natural outcome of *H. pylori* infection in asymptomatic children
- ▶ Extragastrointestinal manifestations of *H. pylori* infection
- ▶ Recent advances in the diagnosis of *H. pylori* infection
- ▶ Emerging first-line anti-*H. pylori* therapy
- ▶ Present status and future prospects of rescue regimens for *H. pylori* infection
- ▶ Vaccinating against *H. pylori*

Authors can submit their manuscripts via the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/bmri/gastroenterology/helico/>.

## Lead Guest Editor

Pin-I Hsu, National Yang-Ming University, Kaohsiung, Taiwan  
[williamhsup@yahoo.com.tw](mailto:williamhsup@yahoo.com.tw)

## Guest Editors

Yoshio Yamaoka, Oita University, Oita, Japan  
[yyamaoka@med.oita-u.ac.jp](mailto:yyamaoka@med.oita-u.ac.jp)

Khean-Lee Goh, University of Malaya Medical Center, Kuala Lumpur, Malaysia  
[klgoh56@gmail.com](mailto:klgoh56@gmail.com)

Marco Manfredi, Azienda Ospedaliero-Universitaria, Parma, Italy  
[marco.manfredi8@gmail.com](mailto:marco.manfredi8@gmail.com)

Deng-Chyang Wu, Kaohsiung Medical University, Kaohsiung, Taiwan  
[dechwu@yahoo.com](mailto:dechwu@yahoo.com)

Varocha Mahachai, Chulalongkorn University, Bangkok, Thailand  
[vmahachai@gmail.com](mailto:vmahachai@gmail.com)

## Manuscript Due

Friday, 5 December 2014

## First Round of Reviews

Friday, 27 February 2015

## Publication Date

Friday, 24 April 2015